Log In
Print
BCIQ
Print
Print this Print this
 

Erwinase, Erwinaze

  Manage Alerts
Collapse Summary General Information
Company Jazz Pharmaceuticals plc
DescriptionErwinia chrysanthemi derived L-asparaginase
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentMarketed
Standard IndicationAcute lymphoblastic leukemia (ALL)
Indication DetailsTreat acute lymphoblastic leukemia (ALL) in patients with hypersensitivity to Escherichia coli-derived asparaginase
Regulatory Designation

U.S. - Orphan Drug (Treat acute lymphoblastic leukemia (ALL) in patients with hypersensitivity to Escherichia coli-derived asparaginase);
U.S. - Priority Review (Treat acute lymphoblastic leukemia (ALL) in patients with hypersensitivity to Escherichia coli-derived asparaginase)

Partner

Ohara Pharmaceutical Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today